Mediatensyl Lp (Urapidil)

Urapidil works by selectively blocking peripheral alpha‑1 adrenergic receptors, causing direct vasodilation of blood vessels. At the same time it stimulates central imidazoline receptors, which reduces sympathetic nervous system outflow, together leading to a decrease in systemic vascular resistance and blood pressure.

The appropriate dose of Mediatensyl Lp is determined by the prescribing clinician based on the patient’s condition, response, and tolerability. Dosage adjustments are made according to blood pressure targets and individual safety considerations.

The safety of Urapidil in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike beta‑blockers or calcium‑channel blockers, Urapidil combines peripheral alpha‑1 blockade with central imidazoline agonism, offering vasodilation without strong reflex tachycardia. This dual mechanism can be advantageous in patients who need rapid blood pressure reduction while minimizing heart rate changes.

Mediatensyl Lp tablets should be stored at ambient temperature, below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Mediatensyl Lp is taken orally as a tablet. It should be swallowed whole with water, preferably at the same times each day, and taken exactly as prescribed by the healthcare provider.

The most serious risks include severe hypotension that can lead to syncope, cardiac arrhythmias, and rare cases of significant liver enzyme elevation. Patients should be monitored closely for signs of these events, especially during dose initiation or adjustment.

Mediatensyl Lp is contraindicated in patients with known hypersensitivity to Urapidil or any tablet excipients, and it should be used with caution in individuals with severe hepatic impairment, uncontrolled heart failure, or those taking monoamine oxidase inhibitors.